Results 111 to 120 of about 1,830,783 (287)

Introducing Borsantrazole: A Trifunctional Boron‐Based Pyrazole That Extends the Lifespan of Amyotrophic Lateral Sclerosis Mice

Advanced Science, EarlyView.
Herein we report a boron‐based pyrazole, (Borsantrazole ‐ a small molecule that selectively targets oxidative stress) that significantly increases survival, reduces weight loss, delays disease onset, and affects global protein changes in the SOD1‐G37R mouse model of ALS.
Nitesh Sanghai, Rhonda Kelley, Ying Lao, M. Immanuel Reyes Madlangsakay, Prasanta Paul, M. Alejandra Llanes‐Cuesta, Jun‐Feng Wang, René P. Zahedi, Jiming Kong, Geoffrey K. Tranmer   +9 more
wiley   +1 more source

Knowledge graph embedding for drug repurposing [PDF]

, 2020
LAUREA MAGISTRALEOggigiorno è fondamentale poter saper rispondere in breve tempo a una nuova malattia che si diffonde. Per questo motivo, un approccio convenzionale non è sufficientemente reattivo.
RAMALLI, EDOARDO
core  

Targeting GALNT7 Disrupts the TAZ O‐GalNAcylation Feedback Loop to Suppress Gallbladder Cancer Progression

Advanced Science, EarlyView.
Aberrant GALNT7‐mediated O‐GalNAcylation stabilizes TAZ to drive gallbladder cancer progression through a feed‐forward transcriptional loop. Structure‐based screening identifies Olaparib as a potent GALNT7 antagonist that disrupts this oncogenic axis, providing an immediate therapeutic strategy for this aggressive malignancy.
Peng Qiu, Ming Zhang, Yunxiang Feng, Yibo Deng, Kai Zhao, Xiangyu Li, Yun Lu, Li Tian, Tao Yang, Wei Yao, Jianming Wang, Zhengdong Deng   +11 more
wiley   +1 more source

Study on Drug Repurposing for ALS Treatment Using Pre-trained Knowledge Graph Embeddings: Methods and Findings

Düzce Üniversitesi Bilim ve Teknoloji Dergisi
In this study, research has been conducted using pre-trained knowledge graph embedding for drug repurposing in treating ALS (Amyotrophic Lateral Sclerosis), and its results have been presented.
Selcan Yalkızımı, Ümit Şentürk
doaj   +1 more source

Drug-disease networks and drug repurposing

PLOS Computational Biology
Abstract Repurposing existing drugs to treat new diseases is a cost-effective alternative to de novo drug development, but there are millions of potential drug-disease combinations to be considered with only a small fraction being viable.
Austin Polanco, Mark E. J. Newman
openaire   +4 more sources

Drug Repurposing Approaches to Combating Viral Infections

, 2020
Development of novel antiviral molecules from the beginning costs an average of $350 million to $2 billion per drug, and the journey from the laboratory to the clinic takes about 10–15 years. Utilization of drug repurposing approaches has generated
Jay Trivedi, Mahesh Mohan, Siddappa N. Byrareddy   +2 more
core   +1 more source

Trafficking Deficiency of TMEM175 Variants in Parkinson's Disease Pathogenesis and the Prospects of Precision Medicine

Advanced Science, EarlyView.
This study identifies that the PD‐associated TMEM175‐L156P variant disrupts lysosomal ion channel trafficking by causing aberrant endoplasmic reticulum retention. A “chaperone–agonist” bifunctional small molecule restores TMEM175‐L156P lysosomal localization and channel function, thereby alleviating PD‐relevant cellular phenotypes and highlighting a ...
Ting Luo, Yu He, Shuyao Li, Haoyu Guan, Ruili Cui, Yu Shi, Zhongwen Jiang, Siyu Wang, Xuan Li, Jiyuan Li, Mei Hu, Yupeng Zhou, Beisha Tang, Yanyan Zhang, Zhaobing Gao, Yu Zhou, Zhenhua Liu, Ping Li   +17 more
wiley   +1 more source

Research and analysis of regulatory framework and harmonisation of repurposing [PDF]

Pharmacia
Drug repurposing is a modern and successful mechanism for discovering new therapeutic indications for authorised medicinal products. There is an absence of a clear definition of the term “drug repurposing” or its synonyms in regulatory frameworks, which ...
Antonio Ivanov, Violeta Getova-Kolarova, Ilko Getov   +2 more
doaj   +3 more sources

Drug Repurposing Using Gene Expression Data Mining [PDF]

, 2023
The conventional drug discovery process that employs the one disease, one target, one drug\u27\u27 paradigm is expensive, time-consuming, and has a high rate of failure for multi-genic complex diseases.
Qiu, Yue
core  

The IRE1‐XBP1s Axis Drives Inflammatory Osteolysis by Regulating a 5‐HT Dependent Endogenous Anti‐Autophagy Mechanism

Advanced Science, EarlyView.
A previously unrecognized IRE1‐XBP1s‐Slc6a4 signaling axis links endoplasmic reticulum stress to serotonin metabolism, autophagy, and inflammatory osteoclastogenesis. By promoting intracellular serotonin uptake and reducing endogenous 3‐methyladenine accumulation, this pathway accelerates inflammatory bone destruction and provides a promising ...
Pengchao Yang, Binxiang Zhu, Yuzhi He, Yang Tian, Honglei Kang, Shian Hu, Pengju Wang, Yong Xu, Zhuowei Lei, Peijun Qi, Hao Yang, Yang Lin, Yimin Dong, Feng Li, Hanfeng Guan   +14 more
wiley   +1 more source